HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shimada, A. Articles by Fathman, C. G. Search for Related Content PubMed PubMed Citation Articles by Shimada, A. Articles by Fathman, C. G. Social Bookmarking                What's this?

Beta-cell destruction may be a late consequence of the autoimmune process in nonobese diabetic mice

The NOD mouse is an animal model of IDDM that shows many of the characteristics of human IDDM. It has been proposed that beta-cell destruction in IDDM progresses over time in a linear manner. Recently, we and others have demonstrated that T helper type 1 (Th1) cells have pathogenic roles in the NOD model and proposed that cytokine balances change as the disease progresses. However, it has not been demonstrated how or when the cytokine balances change or how the beta-cell destruction progresses. We have recently demonstrated that the cytokine profiles of CD45RB(low) CD4+ cells correlate either with their pathogenic or with their protective roles in the NOD mouse. To further analyze this apparent correlation between the shift in cytokine level and IDDM, we examined the anti-CD3-induced cytokine profiles of this subset from NOD mice of various ages compared with that from age-matched I-Ak transgenic NOD and BALB/c mice as controls. A significantly higher ratio of anti-CD3-induced interferon-gamma/interleukin-4 was found in diabetic NOD mice (P < 0.0001) but not in age-matched nondiabetic NOD mice. This cytokine ratio did not change significantly until the onset of diabetes in NOD mice. Based upon these results, we propose that IDDM in the NOD mouse progresses as a predominant inflammatory beta-cell dysfunction without actual beta-cell destruction until late in the disease process. This supports the possibility that late-stage immunotherapy may preserve islet beta-cell mass.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				X. Li, H. Chen, and P. N. Epstein Metallothionein and Catalase Sensitize to Diabetes in Nonobese Diabetic Mice: Reactive Oxygen Species May Have a Protective Role in Pancreatic {beta}-Cells Diabetes, June 1, 2006; 55(6): 1592 - 1604. [Abstract] [Full Text] [PDF]

				T. Shigihara, A. Shimada, Y. Oikawa, H. Yoneyama, Y. Kanazawa, Y. Okubo, K. Matsushima, E. Yamato, J.-i. Miyazaki, A. Kasuga, et al. CXCL10 DNA Vaccination Prevents Spontaneous Diabetes through Enhanced {beta} Cell Proliferation in NOD Mice J. Immunol., December 15, 2005; 175(12): 8401 - 8408. [Abstract] [Full Text] [PDF]

				N. A. Sherry, E. B. Tsai, and K. C. Herold Natural History of {beta}-Cell Function in Type 1 Diabetes Diabetes, December 1, 2005; 54(suppl_2): S32 - S39. [Abstract] [Full Text] [PDF]

				C. Steele, W. A. Hagopian, S. Gitelman, U. Masharani, M. Cavaghan, K. I. Rother, D. Donaldson, D. M. Harlan, J. Bluestone, and K. C. Herold Insulin Secretion in Type 1 Diabetes Diabetes, February 1, 2004; 53(2): 426 - 433. [Abstract] [Full Text]

				Y. Oikawa, A. Shimada, A. Kasuga, J. Morimoto, T. Osaki, H. Tahara, T. Miyazaki, F. Tashiro, E. Yamato, J.-i. Miyazaki, et al. Systemic Administration of IL-18 Promotes Diabetes Development in Young Nonobese Diabetic Mice J. Immunol., December 1, 2003; 171(11): 5865 - 5875. [Abstract] [Full Text] [PDF]

				C. J. Greenbaum and L. C. Harrison Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes Diabetes, May 1, 2003; 52(5): 1059 - 1065. [Full Text] [PDF]

				Y. Oikawa, A. Shimada, S. Yamada, Y. Motohashi, Y. Nakagawa, J.-i. Irie, T. Maruyama, and T. Saruta High Frequency of V{alpha}24+ V{beta}11+ T-Cells Observed in Type 1 Diabetes Diabetes Care, October 1, 2002; 25(10): 1818 - 1823. [Abstract] [Full Text] [PDF]

				T. Lohmann, S. Laue, U. Nietzschmann, T.M. Kapellen, I. Lehmann, S. Schroeder, R. Paschke, and W. Kiess Reduced Expression of Th1-Associated Chemokine Receptors on Peripheral Blood Lymphocytes at Diagnosis of Type 1 Diabetes Diabetes, August 1, 2002; 51(8): 2474 - 2480. [Abstract] [Full Text] [PDF]

				R. H. Friedline, C. P. Wong, D. A. Steeber, T. F. Tedder, and R. Tisch L-Selectin Is Not Required for T Cell-Mediated Autoimmune Diabetes J. Immunol., March 15, 2002; 168(6): 2659 - 2666. [Abstract] [Full Text] [PDF]

				S. Winer, I. Astsaturov, R. Gaedigk, D. Hammond-McKibben, M. Pilon, A. Song, V. Kubiak, W. Karges, E. Arpaia, C. McKerlie, et al. ICA69null Nonobese Diabetic Mice Develop Diabetes, but Resist Disease Acceleration by Cyclophosphamide J. Immunol., January 1, 2002; 168(1): 475 - 482. [Abstract] [Full Text] [PDF]

				A. Shimada, J. Morimoto, K. Kodama, R. Suzuki, Y. Oikawa, O. Funae, A. Kasuga, T. Saruta, and S. Narumi Elevated Serum IP-10 Levels Observed in Type 1 Diabetes Diabetes Care, March 1, 2001; 24(3): 510 - 515. [Abstract] [Full Text]

				S. Winer, L. Gunaratnam, I. Astsatourov, R. K. Cheung, V. Kubiak, W. Karges, D. Hammond-McKibben, R. Gaedigk, D. Graziano, M. Trucco, et al. Peptide Dose, MHC Affinity, and Target Self-Antigen Expression Are Critical for Effective Immunotherapy of Nonobese Diabetic Mouse Prediabetes J. Immunol., October 1, 2000; 165(7): 4086 - 4094. [Abstract] [Full Text] [PDF]

				M. J. Cameron, G. A. Arreaza, M. Grattan, C. Meagher, S. Sharif, M. D. Burdick, R. M. Strieter, D. N. Cook, and T. L. Delovitch Differential Expression of CC Chemokines and the CCR5 Receptor in the Pancreas Is Associated with Progression to Type I Diabetes J. Immunol., July 15, 2000; 165(2): 1102 - 1110. [Abstract] [Full Text] [PDF]

				F. Lepault and M. C. Gagnerault Characterization of Peripheral Regulatory CD4+ T Cells That Prevent Diabetes Onset in Nonobese Diabetic Mice J. Immunol., January 1, 2000; 164(1): 240 - 247. [Abstract] [Full Text] [PDF]

				L. Li, M. Crowley, A. Nguyen, and D. Lo Ability of a Nondepleting Anti-CD4 Antibody to Inhibit Th2 Responses and Allergic Lung Inflammation Is Independent of Coreceptor Function J. Immunol., December 15, 1999; 163(12): 6557 - 6566. [Abstract] [Full Text] [PDF]

				T. Linn, C. Strate, and K. Schneider Diet Promotes {beta}-Cell Loss by Apoptosis in Prediabetic Nonobese Diabetic Mice Endocrinology, August 1, 1999; 140(8): 3767 - 3773. [Abstract] [Full Text]

				E. Bonifacio, M. Scirpoli, K. Kredel, M. Fuchtenbusch, and A.-G. Ziegler Early Autoantibody Responses in Prediabetes Are IgG1 Dominated and Suggest Antigen-Specific Regulation J. Immunol., July 1, 1999; 163(1): 525 - 532. [Abstract] [Full Text] [PDF]

				S. T. Azar, H. Tamim, H. N. Beyhum, M. Z. Habbal, and W. Y. Almawi Type I (Insulin-Dependent) Diabetes Is a Th1- and Th2-Mediated Autoimmune Disease Clin. Vaccine Immunol., May 1, 1999; 6(3): 306 - 310. [Full Text] [PDF]

				W. Y. Almawi, H. Tamim, and S. T. Azar T Helper Type 1 and 2 Cytokines Mediate the Onset and Progression of Type I (Insulin-Dependent) Diabetes J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1497 - 1502. [Abstract] [Full Text]

				A. Amrani, S. Durant, M. Throsby, J. Coulaud, M. Dardenne, and F. Homo-Delarche Glucose Homeostasis in the Nonobese Diabetic Mouse at the Prediabetic Stage Endocrinology, March 1, 1998; 139(3): 1115 - 1124. [Abstract] [Full Text] [PDF]

				L. Yu, D. T. Robles, N. Abiru, P. Kaur, M. Rewers, K. Kelemen, and G. S. Eisenbarth Early expression of antiinsulin autoantibodies of humans and the NOD mouse: Evidence for early determination of subsequent diabetes PNAS, February 15, 2000; 97(4): 1701 - 1706. [Abstract] [Full Text] [PDF]